for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Johnson & Johnson

JNJ.N

Latest Trade

127.70USD

Change

-8.47(-6.22%)

Volume

6,013,033

Today's Range

127.70

 - 

134.38

52 Week Range

122.00

 - 

148.97

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Johnson & Johnson Consumer Inc To Voluntarily Recall Single Lot Of Johnson's Baby Powder In U.S.

Oct 18 (Reuters) - Johnson & Johnson Consumer Inc::JOHNSON & JOHNSON CONSUMER INC. TO VOLUNTARILY RECALL A SINGLE LOT OF JOHNSON'S BABY POWDER IN THE UNITED STATES.SAYS RECALL LIMITED TO ONE LOT OF BOTTLES PRODUCED AND SHIPPED IN U.S. IN 2018.SAYS JJCI IS INITIATING VOLUNTARY RECALL OF LOT #22318RB OF JOHNSON'S BABY POWDER, FROM WHICH TESTED SAMPLE WAS TAKEN.SAYS RECALL IN RESPONSE TO FDA TEST INDICATING PRESENCE OF SUB-TRACE LEVELS OF CHRYSOTILE ASBESTOS CONTAMINATION IN SAMPLES FROM SINGLE BOTTLE BOUGHT FROM ONLINE RETAILER.SAYS AT THIS EARLY STAGE OF INVESTIGATION, JJCI CANNOT CONFIRM IF CROSS-CONTAMINATION OF SAMPLE CAUSED A FALSE POSITIVE.SAYS CANNOT CONFIRM IF SAMPLE WAS TAKEN FROM A BOTTLE WITH INTACT SEAL OR WHETHER SAMPLE WAS PREPARED IN CONTROLLED ENVIRONMENT.SAYS CANNOT CONFIRM WHETHER TESTED PRODUCT IS AUTHENTIC OR COUNTERFEIT.SAYS INITIATED INVESTIGATION INTO MATTER WHERE FDA'S TEST INDICATED PRESENCE OF SUB-TRACE LEVELS OF CHRYSOTILE ASBESTOS CONTAMINATION IN SAMPLES OF A BABY POWDER BOTTLE.SAYS JJCI IS WORKING WITH FDA TO DETERMINE INTEGRITY OF TESTED SAMPLE, VALIDITY OF TEST RESULTS.

Johnson & Johnson Announces Quarterly Dividend For Fourth Quarter 2019

Oct 17 (Reuters) - Johnson & Johnson <JNJ.N>::JOHNSON & JOHNSON ANNOUNCES QUARTERLY DIVIDEND FOR FOURTH QUARTER 2019.SETS QUARTERLY CASH DIVIDEND OF $0.95PER SHARE.

J&J Says Does Not Expect $8 Bln Risperdal Judgement To Stand; Says Will Appeal

Oct 15 (Reuters) - Johnson & Johnson <JNJ.N>::J&J SAYS OVER 2,000 CENTERS CERTIFIED FOR PROVIDING DEPRESSION TREATMENT SPRAVATO - CONF CALL.J&J CFO SAYS EXPECTS EVEN HIGHER LEVELS OF INVESTMENT IN Q4 IN AREAS INCLUDING CAR-T THERAPIES AND LINE EXTENSIONS WITHIN IMMUNOLOGY - CONF CALL.J&J CFO SAYS EXPECTS PHARMACEUTICAL UNIT TO DELIVER SALES ABOVE MARKET - CONF CALL.J&J CFO SAYS "WE DO EXPECT TO BE ABOVE MARKET, BUT JUST NOT AS PRONOUNCED AS WE WOULD HAVE THOUGHT IN THE BEGINNING OF THIS YEAR FOR 2020" - CONF CALL.J&J CFO SAYS SHARE REPURCHASE IS "PROBABLY LEAST OF OUR PREFERRED OPTIONS" IN CAPITAL ALLOCATION STRATEGY - CONF CALL.J&J EXECUTIVE SAYS U.S. SURGICAL BUSINESS CHALLENGED DUE TO COMPETITIVE INROADS AND SOME SOFTENING IN THE LASIK MARKET - CONF CALL.J&J SAYS DOES NOT EXPECT $8 BILLION RISPERDAL JUDGEMENT TO STAND; SAYS WILL APPEAL - CONF CALL.J&J SAYS WILL CONTINUE TO DEFEND TALC PRODUCTS THAT CO KNOWS TO BE SAFE AND DOES NOT CAUSE CANCER ACCORDING TO EXPERTS IN THE FIELD - CONF CALL.J&J EXECUTIVE SAYS EXPECTS TO SEE MODERATE ACCELERATION IN REVENUE FROM CONSUMER PRODUCTS IN 2020 - CONF CALL.

Johnson & Johnson Reports 2019 Third-Quarter Results

Oct 15 (Reuters) - Johnson & Johnson <JNJ.N>::REPORTS 2019 THIRD-QUARTER RESULTS.Q3 ADJUSTED EARNINGS PER SHARE $2.12.Q3 EARNINGS PER SHARE $1.81.Q3 EARNINGS PER SHARE ESTIMATE $2.01 -- REFINITIV IBES DATA.Q3 REVENUE $20.7 BILLION VERSUS REFINITIV IBES ESTIMATE OF $20.07 BILLION.J&J - COMPANY INCREASING FULL YEAR SALES AND EPS GUIDANCE DUE TO STRONG PERFORMANCE.J&J - INCREASING FULL YEAR SALES AND EPS GUIDANCE.J&J SEES FY ADJUSTED EPS $8.62 TO $8.67.J&J SEES FY ADJUSTED OPERATIONAL EPS $8.84 TO $8.89.J&J - SEES FY ADJUSTED OPERATIONAL SALES UP 4.5% - 5.0%.J&J - SEES FY OPERATIONAL SALES $83.7 BILLION TO $84.2 BILLION.J&J - SEES FY ESTIMATED REPORTED SALES $81.8 BILLION TO $82.3 BILLION.J&J - NINE MONTHS YTD GAAP LITIGATION EXPENSE $832 MILLION VERSUS $703 MILLION REPORTED LAST YEAR.FY2019 EARNINGS PER SHARE VIEW $8.60, REVENUE VIEW $81.48 BILLION -- REFINITIV IBES DATA.

Johnson & Johnson Reports Q3 Remicade Sales Of $1.14 Bln

Oct 15 (Reuters) - Johnson & Johnson <JNJ.N>::J&J - QUARTERLY WORLDWIDE REMICADE SALES $1,136 MILLION VERSUS $1,379 MILLION REPORTED LAST YEAR.J&J - QUARTERLY WORLDWIDE ZYTIGA SALES $741 MILLION VERSUS $958 MILLION.J&J - QUARTERLY WORLDWIDE IMBRUVICA SALES $921 MILLION VERSUS $705 MILLION.

U.S. FDA Approves XARELTO (Rivaroxaban) To Help Prevent Blood Clots In Acutely Ill Medical Patients

Oct 14 (Reuters) - Johnson & Johnson <JNJ.N>::U.S. FDA APPROVES XARELTO® (RIVAROXABAN) TO HELP PREVENT BLOOD CLOTS IN ACUTELY ILL MEDICAL PATIENTS.JANSSEN - FDA HAS APPROVED XARELTO TO HELP PREVENT BLOOD CLOTS IN ACUTELY ILL MEDICAL PATIENTS.

Johnson's Baby Powder Was Not The Cause Of California Plaintiff's Disease, says J&J Spokesman

Oct 10 (Reuters) - Johnson & Johnson <JNJ.N>::JOHNSON’S BABY POWDER DOES NOT CONTAIN ASBESTOS AND WAS NOT THE CAUSE OF CALIFORNIA PLAINTIFF’S DISEASE - J&J SPOKESMAN.J&J SPOKESMAN ON VERDICT OF CALIFORNIA JURY IN TALC CANCER RETRIAL SAYS "THIS IS THE SEVENTH JURY THAT HAS FOUND IN FAVOR OF JOHNSON & JOHNSON".

Amneal Announces Launch Of Generic Invega

Oct 10 (Reuters) - Amneal Pharmaceuticals Inc <AMRX.N>::AMNEAL ANNOUNCES LAUNCH OF GENERIC INVEGA®.AMNEAL PHARMACEUTICALS INC - HAS LAUNCHED ITS GENERIC VERSION OF INVEGA (PALIPERIDONE) EXTENDED-RELEASE TABLETS, 1.5 MG, 3 MG, 6 MG, AND 9 MG.

J&J Says Ronald Kapusta, Controller & Chief Accounting Officer, To Retire, Effective Dec 27, 2019

Oct 7 (Reuters) - Johnson & Johnson <JNJ.N>::J&J - ON OCTOBER 7, 2019, ANNOUNCED RONALD A. KAPUSTA, CONTROLLER AND CHIEF ACCOUNTING OFFICER, HAS ELECTED TO RETIRE, EFFECTIVE DEC 27, 2019.J&J - ROBERT J. DECKER, JR. HAS BEEN APPOINTED CONTROLLER AND CHIEF ACCOUNTING OFFICER, EFFECTIVE DEC. 27.

Janssen Submits Application To U.S. FDA Seeking Approval Of Stelara

Oct 7 (Reuters) - Johnson & Johnson <JNJ.N>::JANSSEN SUBMITS APPLICATION TO U.S. FDA SEEKING APPROVAL OF STELARA®(USTEKINUMAB) FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS.JANSSEN SUBMITS APPLICATION TO U.S. FDA SEEKING APPROVAL OF STELARA®(USTEKINUMAB) FOR TREATMENT OF PEDIATRIC PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up